Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30730257 | 0.92 | CTNNB1 (0.47) | RAB9ANPC1POLBCASP3CASP7 | |
| SCHEMBL26087589 | 0.88 | CHRM2 (0.48) | RAB9AALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL3226201 | 0.86 | RAB9A (0.52) | RAB9ANPC1POLBCASP3CASP7 | |
| SCHEMBL19926744 | 0.83 | SMN1; SMN2 (0.57) | RAB9ANPC1ALDH1A1GAAGFER | |
| SCHEMBL4678364 | 0.83 | RAB9A (0.52) | RAB9ANPC1POLBCASP3CASP7 | |
| SCHEMBL13818491 | 0.82 | RAB9A (0.46) | RAB9ANPC1POLBCASP3CASP7 | |
| SCHEMBL1346356 | 0.82 | ALDH1A1 (0.43) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL2777357 | 0.81 | RAB9A (0.52) | RAB9ANPC1POLBCASP3CASP7 | |
| SCHEMBL1403662 | 0.81 | FABP4 (0.56) | RAB9ANPC1POLBCASP3CASP7 | |
| SCHEMBL31409466 | 0.81 | SMN1; SMN2 (0.51) | RAB9ANPC1ALDH1A1GAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269505-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-10-30 | — | — | US | claimed |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-30 | — | — | US | claimed |
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20240409550-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4464317-A2 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | Sumitomo Pharma America, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-3494119-B1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA INC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-11958862-B2 | Compounds and compositions and uses thereof | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| CN-116514761-A | Compounds, compositions and uses thereof | 赛诺维信制药公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116283877-A | Compounds, compositions and uses thereof | 赛诺维信制药公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-110088107-B | Compounds, compositions and uses thereof | 赛诺维信制药公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20220340588-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-27 | — | — | US | disclosed |
| EP-1966179-A2 | DARIFENACIN HYDROBROMIDE COMPOSITION SUBSTANTIALLY FREE OF OXIDIZED DARIFENACIN AND SALTS THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | Teva Pharmaceutical Industries Ltd (IL) | 2008-09-10 | — | — | EP | disclosed |
| US-20080214835-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-09-04 | — | — | US | disclosed |
| US-20080214846-A1 | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-09-04 | — | — | US | disclosed |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-30 | — | — | US | disclosed |
| US-20070197630-A1 | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2007-08-23 | — | — | US | disclosed |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | US | disclosed |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | US | disclosed |
| WO-2007076158-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076159-A2 | PURE DARIFENACIN HYDROBROMIDE SUBSTANTIALLY FREE OF OXIDIZED DARIFENACIN AND SALTS THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214835-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | RAB9A 956/4885NPC1 4114/4885POLB 587/4885 |
| US-20240409550-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | RAB9A 1501/4885NPC1 166/4885POLB 2304/4885 |
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ADH1C, HTR6, CNR1 | RAB9A 1637/4885NPC1 137/4885POLB 2989/4885 |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | CHRNE, CHRM3, CHRM2 | RAB9A 3273/4885NPC1 4762/4885POLB 2444/4885 |
| US-11958862-B2 | Compounds and compositions and uses thereof | CHAT, ACHE, MAOB | RAB9A 1501/4885NPC1 166/4885POLB 2304/4885 |
| US-20070197630-A1 | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof | OPRL1, OPRK1, OPRD1 | RAB9A 1486/4885NPC1 4332/4885POLB 640/4885 |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | RAB9A 956/4885NPC1 4114/4885POLB 587/4885 |
| US-20220340588-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | RAB9A 1501/4885NPC1 166/4885POLB 2304/4885 |
| US-20080269505-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | RAB9A 956/4885NPC1 4114/4885POLB 587/4885 |
| US-20080214846-A1 | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof | OPRL1, OPRK1, OPRD1 | RAB9A 1486/4885NPC1 4332/4885POLB 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.